

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>BIOGEN IDEC INC</u> <hr/> (Last) (First) (Middle) <u>14 CAMBRIDGE CENTER</u> <hr/> (Street) <u>CAMBRIDGE MA 02142</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>09/25/2002</u>	3. Issuer Name and Ticker or Trading Symbol <u>TARGETED GENETICS CORP /WA/ [TGEN]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, \$0.01 Par Value	3,060,754 ⁽¹⁾	I	By Biogen Idec MA, Inc. ⁽²⁾
Common Stock, \$0.01 Par Value	851,873 ⁽³⁾	I	By Biogen Idec MA, Inc. ⁽²⁾
Common Stock, \$0.01 Par Value	508,673 ⁽⁴⁾	I	By Biogen Idec MA, Inc. ⁽²⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

1. Name and Address of Reporting Person* <u>BIOGEN IDEC INC</u> <hr/> (Last) (First) (Middle) <u>14 CAMBRIDGE CENTER</u> <hr/> (Street) <u>CAMBRIDGE MA 02142</u> <hr/> (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person* <u>BIOGEN IDEC MA INC</u> <hr/> (Last) (First) (Middle) <u>14 CAMBRIDGE CENTER</u> <hr/> (Street) <u>CAMBRIDGE MA 02142</u> <hr/> (City) (State) (Zip)		
---	--	--

Explanation of Responses:

- The reporting person received these shares on 9/19/2000 in exchange for its shares of Genovo, Inc. in the merger of a subsidiary of Targeted Genetics Corporation with and into Genovo.
- Shares are owned indirectly by Biogen Idec Inc. and directly by its wholly-owned subsidiary Biogen Idec MA, Inc., fka Biogen, Inc.
- The reporting person received these shares on 9/19/2000 as consideration for the return to Genovo of certain intellectual property and other rights in connection with the merger described in footnote 1.
- The reporting person purchased these shares on 9/25/2002 upon exercise by Targeted Genetics of its right to put such shares to the reporting person for purchase under the Funding Agreement dated as of August 8, 2000 between Targeted Genetics and the reporting person.

Remarks:

Exhibit List Exhibit 99- Joint Filer Information

/s/ Raymond G. Arner, Acting 07/12/2005
General Counsel

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 3 Joint Filer Information

Name: Biogen Idec MA, Inc.

Address: 14 Cambridge Center
Cambridge, Massachusetts 02142

Designated Filer: Biogen Idec Inc.

Issuer and Ticker Symbol: Targeted Genetics Corporation (TGEN)

Date of Earliest
Transaction Required
to be Reported: September 25, 2002

Signature: By: /s/ Michael Phelps
Name: Michael Phelps
Title: Treasurer